BTA injections can treat infantile esotropia

Article

Botulinum toxin type A (BTA) injections, with or without sodium hyaluronate (SH), are effective and feasible for the treatment of infantile esotropia.

Botulinum toxin type A (BTA) injections, with or without sodium hyaluronate (SH), are effective and feasible for the treatment of infantile esotropia, claims a paper in the journal Eye.

The investigation, led by Dr J. Chen, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Centre, Sun Yat-sen University, Guangzhou, China, included 47 patients with infantile esotropia who were randomly divided into two groups. Group A included 23 cases treated with bilateral injection of 2.5–3.75 U BTA combined with sodium hyaluronate (SH). In group B 24 patients were administered the BTA solution with SH. All patients did not undergo electromyography and injections were evaluated two weeks, three months and six months postoperatively.

Both groups presented with good alignment six months after injections, with group A at 30.4% and group B at 37.5%. Complicated ptosis and vertical deviation were 2.2% vs 20.8% and 2.2% vs 2.1% in groups A and B, respectively.

BTA injections with or without SH produced similar results and demonstrated effectiveness and feasibility. However, BTA injections with SH relatively decrease the frequency of complicated ptosis.

The abstract can be read here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.